Abstract
Apart from its use in endocrinology and rheumatology, therapeutic nuclear medicine is developing rapidly as an additional treatment modality in oncology. Many different specific tumour-seeking radiopharmaceuticals are being applied both for diagnostic scintigraphy and treatment, using multiple routes and mechanisms to target radionuclides at tumours. After a brief introduction of some basic principles of radionuclide targeting, the therapeutic radiopharmaceuticals available are reviewed according to the accumulation site in relation to the cell nucleus; the results of their current clinical use for therapy are also reviewed. The response observed to a number of these applications, the non-invasiveness of the procedure and the relative lack of toxicity and late effects in comparison with chemotherapy and external beam radiotherapy make radionuclide therapy an attractive and realistic alternative in the management of malignant disease, as well as in the treatment of a few benign disorders.
Similar content being viewed by others
References
Ackerman NB, Hechmer PA (1980) The blood supply of experimental liver metastases. V. Increased tumor perfusion with epinephrine. Am J Surg 140:625–631
Ackery DM, Lewington V (1991) The treatment of malignant pheochromocytoma with MIBG. In: Clinical endocrinology. Blackwell Scientific, Oxford (in press)
Adelstein SJ, Kassis AI (1987) Radiobiologic implications of the microscopic distribution of energy from radionuclides. Int J Rad Appl Instrum [B] 14:165–169
Adolph J, Kimmig B, Eisenhut M, Georgi P, Winkel K zum (1986) Therapy of carcinoid tumors with131I-meta-iodo-benzylguani-dine. Nucl Med 25:A58
Ansell BM, Crook A, Mallard JR, Bywaters EGL (1963) Evaluation of intra-articular colloidal gold Au 198 in the treatment of persistent knee effusions. Ann Rheum Dis 22:435–439
Askienazy S, Turak B, Piketty ML, Munari C, Habert MO, Lebtahi R, Dlouya A, Chodkiewicz JP (1990) Colloidal 186 Re in the endocavitary irradiation of cystic craniopharyngiomas. Eur J Nucl Med 16:S143
Baulieu J-L, Guilloteau D, Baulieu F, Le Floch O, Chambon C, Pourcelot L, Besnard JC (1988) Therapeutic effectiveness of iodine-131 MIBG metastases of a nonsecreting paraganglioma. J Nucl Med 29:2008–2013
Becker DV (1982) Radioactive iodine (131l) in the treatment of hyperthyroidsim. In: Tubiana M (ed) Thyroid diseases. Pergamon Press, Oxford, pp 145–158
Becker DV, McConahey W, Dobyns B, Tompkins E, Sheline G, Workman J (1971) The results of radioiodine treatment of hyperthyroidism. A preliminary report of the thyrotoxicosis therapy follow-up study. In: Fellinger K, Höfer R (eds) Further advances in thyroid research, vol 1. Verlag der Wiener Medizinischen Akademie, Vienna, pp 603–609
Beierwaltes WH (1985a) New horizons for therapeutic nuclear medicine in 1984. In: Schmidt HAE, Vauramo DE (eds) Nuclear medicine in research and practice. Schattauer, Stuttgart, pp L I-V
Beierwaltes WH (1985b) Horizons in radionulide therapy: 1985 update. J Nucl Med 26:421–427
Beierwaltes WH (1986) Therapy of malignant thyroid disease. In: Pauwels EKJ, Schoot JB van der, Voorthuisen AE van (eds) Nucleaire Geneeskunde oud en nieuw. Boerhaave Commissie voor Postacademisch Onderwijs in de Geneeskunde, Leiden, pp 85–98
Beierwaltes WH, Nishiyama RH, Thompson NW, Copp JE, Kubo A (1982) Survival time and “cure” in papillary and follicular thyroid carcinoma with distant metastases: statistics following University of Michigan therapy. J Nucl Med 23:561–568
Beierwaltes WH, Rabbani R, Dmuchowski C, Lloyd RV, Eyre P, Mallette S (1984) An analysis of “ablation of thyroid remnants” with 1–131 in 511 patients from 1947-1984: experience at University of Michigan. J Nucl Med 25:1287–1293
Belfer AJ, Grijm R, Van der Schoot JB (1979) Hepatic adenoma imaging with different radionuclides. Clin Nucl Med 4:375–378
Benua RS, Cicale NR, Sonenberg M, Rawson RW (1962) The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. Am J Roentgen 87:171–182
Bestagno M, Guerra P, Puricelli GP, Colombo L, Calculli G (1987) Treatment of neuroblastoma with131I-metaiodobenzylguani-dine: the experience of an Italian study group. Med Pediat Oncol 15:203–205
Blake GM, Zivanovic MA, McEwan AJ, Ackery DM (1986) Sr-89 therapy: strontium kintics in disseminated carcinoma of the prostate. Eur J Nucl Med 12:447–454
Blake GM, Zivanovic MA, McEwan AJ, Condon BR, Ackery DM (1987) Strontium-89 therapy: strontium kinetics and dosimetry in two patients treated for metastasising osteosarcoma. Br J Radiol 60:253–259
Blake GM, Zivanovic MA, Blaquiere RM, Fine DR, McEwan AJ, Ackery DM (1988a) Strontium-89 therapy: measurement of absorbed dose to skeletal metastases. J Nucl Med 29:549–557
Blake GM, Lewington VJ, Fleming JS, Zivanovic MA, Ackery DM (1988b) Modification by nifedipine of131I-meta-iodoben-zylguanidine kinetics in malignant phaeochromocytoma. Eur J Nucl Med 14:345–348
Bloomer WD, McLaughlin WH, Weichselbaum RR, Tonnesen GL, Hellman S, Seitz DE, Hanson RN, Adelstein SJ, Rosner AL, Burstein NA, Nove JJ, Little JB (1980) Iodine-125-labelled tamoxifen is differentially cytoxic to cells containing oestrogen receptors. Int J Radiat Biol 38:197–202
Bloomer WD, McLaughlin WH, Adelstein SJ (1982) Therapeutic implications of iodine-125 cytotoxicity. Int J Radiat Oncol Biol Phys 8:1903–1908
Boerbooms AMTh, Buijs WCAM, Danen M, Putte LBA van de, Vandenbroucke JP (1985) Radiosynovectomy in chronic synovitis of the knee joint in patients with rheumatoid arthritis. Eur J Nucl Med 10:446–449
Boussina I, Toussaint M, Ott H, Hermans P, Fallet GH (1979) A double-blind study of Erbium 169 synoviorthesis in rheumatoid digital joints. Results after one year. Scand J Rheumatol 8:71–74
Boye E, Lindegaard MW, Paris E, Skretting A, Davy M, Jakobsen E (1984) Whole body distribution of radioactivity after intraperitoneal administration of32P colloids. Br J Radiol 57:395–402
Bretagne J-F, Raoul JL, Bourguet P, Duvauferrier R, Deugnier Y, Faroux R, Ramée A, Herry J-Y, Gastard J (1988) Hepatic artery injection of I-131 labeled lipiodol. Part I. Biodistribution study. Results in patients with hepatocellular carcinoma and liver metastases. Radiology 168:541–545
Brown AP, Greening WP, McCready VR, Shaw HJ, Harmer CL (1984) Radioiodine treatment of metastatic thyroid carcinoma: The Royal Marsden Hospital experience. Br J Radiol 57:323–327
Cheung A, Driedger AA (1980) Evaluation of radioactive phosphorus in the palliation of metastatic bone lesions from carcinoma of the breast and prostate. Radiology 134:209–212
Cheung NKV, Yeh SDJ, Kushner BH, Burch L, Gulati S, Larson S (1990) Radioimmunotherapy using 131-I-3178 in neuroblastoma (NB): a phase I clinical trial. Med Pediat Oncol 18:380
Clarke SE, Lazarus CR, Edwards S, Murby B, Clarke DG, Roden TM, Fogelman I, Maisey MN (1987) Scintigraphy and treatment of medullary carcinoma of the thyroid with iodine-131 metaiodobenzylguanidine. J Nucl Med 28:1820–1825
Clarke SEM, Lazarus CR, Wraight P, Sampson C, Maisey MN (1988) Pentavalent99mTc-DMSA,131I-MIBG and99mTc-MDP - an evaluation of three imaging techniques in patients with medullary carcinoma of the thyroid. J Nucl Med 29:33–38
Clarke SEM, Blower P, Allen SJ, Blake GM, McKeeney DB, Lazarus CR, Singh J, Page C (1990) Re-186-V-DMSA: a new radiopharmaceutical for therapy of medullary carcinoma of the thyroid. Eur J Nucl Med 16: S70
Cobb LM, Butler SA (1987) Treatment of the murine lymphoma A31 with intravenous, sterilized141mIn-loaded A31 cells. Radiother Oncol 10:217–230
Correns J-J, Buchali K, Schnorr D, Lips H, Sydow K, Schürere M, Johannsen B (1986) On the efficacy of strontium-89 therapy. Preliminary evaluation of a double-blind study. In: Winkler C (ed) Nuclear medicine in clinical oncology. Springer, Berlin Heidelberg New York, pp 345–347
Cottino F, Mussa GC, Madon E, Favero A, Silvestro L, Grazia G (1987)131I-metaiodobenzylguanidine treatment in neuroblastoma: report of two cases. Med Pediat Oncol 15:216–219
Creutzig H, Funke-Voelkers R, Kroenke C, Guth B, Henning A, Müller St (1987) Risk factors in differentiated thyroid cancer. J Nucl Med 28:576
DeGroot LJ, Reilly M (1982) Comparison of 30- and 50-mCi doses of iodine-131 for thyroid ablation. Ann Int Med 96:51–53
De Kraker J, Hoefnagel CA, Voûte PA (1989) J131 Rose Bengal therapy in inoperable hepatoblastoma. Med Pediat Oncol 17:278
De Kraker J, Voûte PA, Hoefnagel CA (1990) Induction therapy with J131-MIBG in neuroblastoma advanced disease patients. Med Pediat Oncol 18:380
De Kraker J, Hoefnagel CA, Voûte PA (1991) Is131I-Rose Bengal therapy feasible in hepatoblastoma patients? Eur J Cancer (in press)
DeNardo SJ, DeNardo GL, O'Grady LF, Hu E, Sytsma VM, Mills SL, Levy NB, Macey DJ, Miller CH, Epstein AL (1988) Treatment of B-cell malignancies with 1311 Lym-1 monoclonal antibodies. Int J Cancer [Suppl] 3:96–101
DeNardo GL, DeNardo SL, Mills SN, Lewis JP, O'Grady LF, Levy NB (1990) Treatment of B cell malignancies in patients using I-131 Lym-1. J Nucl Med 31:723–724
DeSombre ER, Mease RC, Hughes A, Harper PV, DeJesus OT, Friedman AM (1988a) Bromine-80m-labeled estrogens: Auger electron-emitting, estrogen receptor-directed ligands with potential for therapy of estrogen receptor-positive cancers. Cancer Res 48:899–906
DeSombre ER, Harper PV, Hughes A, Mease RC, Gatley SJ, DeJesus OT, Schwartz JL (1988b) Bromine-80m radiotoxicity and the potential for estrogen receptor-directed therapy with Auger electrons. Cancer Res 48:5805–5809
Divgi CR, Larson SM (1989) Radiolabeled monoclonal antibodies in the diagnosis and treatment of malignant melanoma. Semin Nucl Med 19:252–261
Dobyns BM, Maloof K (1951) The study and treatment of 119 cases of carcinoma of the thyroid with radioactive iodine. J Clin Endocrinol 11:1323–1369
Döge H, Hliscs R (1984) Intrathecal therapy with198Au-colloid for meningosis prophylaxis. Eur J Nucl Med 9:125–128
Eary JF, Press OW, Badger CC, Durack LD, Richter KY, Addison SJ, Krohn KA, Fisher DR, Porter BA, Williams DL, Martin PJ, Appelbaum FR, Levy R, Brown SL, Miller RA, Nelp WB, Bernstein ID (1990) Imaging and treatment of B-cell lymphoma. J Nucl Med 31:1257–1268
Edmonds CJ, Smith T (1986) The long-term hazards of the treatment of thyroid cancer with radioiodine.Br J Radiol 59:45–51
Ehrhardt GJ, Day DE (1987) Therapeutic use of90Y microspheres. Nucl Med Biol 14:233–242
Eisenhut M, Berberich R, Kimmig B, Oberhausen E (1986) Iodine131-labeled diphosphonates for palliative treatment of bone metastases. 11. Preliminary clinical results with131I-BDP3. J Nucl Med 27:167–174
E.O.R.T.C. (1981) Treatment of polycythaemia vera by radiophosphorus or Busulphan: a randomized trial. Br J Cancer 44:75–80
Epenetos AA, Munro AJ, Stewart S, Rampling R, Lambert HE, McKenzie CG, Soutter P, Rahemtulla A, Hooker G, Sivolapenko GB, Snook D, Courtenay-Luck N, Dhokia B, Krausz T, Taylor-Papdimitriou J, Durbin H, Bodmer WE (1987) Antibody-guided irradiation of advanced ovarian cancer with intraperitoneally administered radiolabeled monoclonal antibodies. J Clin Oncol 5:1890–1899
Fielding SL, Flower MA, Ackery DM, Kemshead JT, Lashford LS, Lewis I (1991) The dosimetry of131I mIBG for treatment of resistant neuroblastoma - results of a UK study. Eur J Nucl Med (in press)
Finkler NJ, Kassis AI, Muto MG, Weadock K, Tumeh SS, Zurawski Jr VR, Knapp RC (1989) Intraperitoneal radioiodinated OC 125 in patients with advanced ovarian cancer: phase I study. J Nucl Med 30:904
Firusian N (1980)32P-therapy for malignant pericardial effusion. Onkologie 3:12–17
Firusian N, Schmidt CG (1977) Ergebnisse der endoossalen Therapie. In: Schmidt HAE, Woldring M (eds) Nuklearmedizin. Schattauer, Stuttgart, pp 374–379
Fischer M, Vetter H (1986) Treatment of pheochromocytomas with 1311-metaiodobenzylguanidine. In: Winkler C (ed) Nuclear medicine in clinical oncology. Springer, Berlin Heidelberg New York, pp 327–330
Fischer M, Wehinger H, Kraus C, Ritter J, Schröter W (1987) Treatment of neuroblastoma with131I-metaiodobenzylguani-dine: experience of the Münster/Kassel group. Med Pediat Oncol 15:196–199
Fischman AJ, Khaw BA, Strauss WH (1989) Quo vadis radioimmune imaging. J Nucl Med 30:1911–1915
Franssen MJAM, Boerbooms AMTh, Karthaus RP, Buijs WCAM, Putte LBA van de (1989) Treatment of pigmented villonodular synovitis of the knee with yttrium-90 silicate: prospective evaluations by arthroscopy, histology and99mTc pertechnetate uptake measurements. Ann Rheum Dis 48:1007–1013
Freitas JE, Gross MD, Ripley S, Shapiro B (1985) Radionuclide diagnosis and therapy of thyroid cancer: current status report. Semin Nucl Med 15:106–131
Goldenberg DM (1989) Future role of radiolabeled monoclonal antibodies in oncological diagnosis and therapy. Semin Nucl Med 19:332–339
Guerra P, Colombo L, Maira G, Pagliaini R, Terzi A, Pizzocaro C, Puricelli A, Bestagno M (1990) 1311-MIBG in the treatment of carcinoid tumor. In: Schmidt HAE, Chambron J (eds) Nuclear medicine - quantitative analysis in imaging and function. Schattauer, Stuttgart, pp 583–585
Gumpel JM, Roles NC (1975) A controlled trial of intraarticular radiocolloids versus surgical synovectomy in persistent synovitis. Lancet 1:488–489
Halnan KE (1977) The treatment of thyroid cancer. Ann Radiol 20:826–830
Halnan KE, Russell MH (1965) Polycythemia vera. Comparison of survival and causes of death in patients managed with and without radiotherapy. Lancet 11:760–763
Hamilton D, Cowan RA, Sharma HL, Drayson M, Nuttall PM, Wagstaff J, Deakin DP, Crowther D (1988) The behaviour of autologous indium-114-labeled lymphocytes in patients with lymphoid cell malignancy. J Nucl Med 29:485–493
Harbert JC (1987) Nuclear medicine therapy. Thieme, Stuttgart New York
Harman JB, Ledlie EM (1976) Survival of polycythemia vera patients treated with radioactive phosphorus. Br Med J 11:146
Hartmann O, Lumbroso J, Lemerle J, Schlumberger M, Ricard M, Aubert B, Coornaert S, Merlin L, Olive D, De Lumley L, Parmentier C (1987) Therapeutic use of131I-metaiodoben-zylguanidine (MIBG) in neuroblastoma: a phase II study in nine patients. Med Pediat Oncol 15:205–211
Haynie TP, Beierwaltes WH (1963) Hematologic changes observed following I-131 therapy for thyroid carcinoma. J Nucl Med 4:85–91
Herba MJ, Illescas FF, Thirlwell MP, Boos GJ, Rosenthall L, Atri M, Bret PM (1988) Hepatic malignancies: improved treatment with intraarterial Y-90. Radiology 169:311–314
Hnatowich DJ, Chinol M, Siebecker DA, Gionet M, Griffin T, Doherty PW, Hunter R, Kase KR (1988) Patient distribution of intraperitoneally administered Yttrium-90-labelled antibody. J Nucl Med 29:1428–1434
Hnatowich DJ, Stevens S, Kinders RJ, Ruschowski M, Rose P, Hunter R, Griffin T, Brill AB (1989) Intraperitoneal yttrium-90 immunotherapy in ovarian cancer patients. J Nucl Med 30:828
Hoefnagel CA (1989) The clinical use of131I-meta-iodobenzyl-guanidine (MIBG) for the diagnosis and treatment of neural crest tumors. Thesis, University of Amsterdam
Hoefnagel CA, Bruning PF, Cohen P, Marcuse HR, Van der Schoot JB (1981) Detection of lung metastases from osteosarcoma by scintigraphy using99mTc-methylene diphosphonate. Diagn Imaging 50:277–284
Hoefnagel CA, Hartog Jager FCA den, van Gennip AH, Marcuse HR, Taal BG (1986) Diagnosis and treatment of a carcinoid tumor using I-131-metaiodobenzylguanidine. Clin Nucl Med 11:150–152
Hoefnagel CA, Voûte PA, Kraker J de, Marcuse HR (1987a) Radionuclide diagnosis and therapy of neural crest tumors using Iodinel31 metaiodobenzylguanidine. J Nucl Med 28:308–314
Hoefnagel CA, Hartog Jager FCA den, Taal BG, Abeling NGGM, Engelsman EE (1987b) The role of I-131-MIBG in the diagnosis and therapy of carcinoids. Eur J Nucl Med 13:187–191
Hoefnagel CA, Marcuse HR, Kraker J de, Voûte PA (1987c) Methodik and Problematik der I-131-MIBG-szintigraphie mit SPELT. Nuklearmediziner 4:317–323
Hoefnagel CA, Smets L, Voûte PA, Kraker J de (1991a) Iodine125-MIBG therapy for neuroblastoma. J Nucl Med 32:361–362
Hoefnagel CA, Valdes Olmos RA, Delprat CC (1991b) Therapy of medullary thyroid carcinoma using 1-131 MIBG and radiolabelled monoclonal antibodies. In: Calmettes C (ed) Medullary thyroid carcinoma, Libbey, London (in press)
Houle S, Yip K, Shepperd FA, Rotstein LE, Paul K, Sniderman KW (1990) Intraarterial yttrium-90 glass microspheres for internal radiation therapy of hepatocellular carcinoma. Eur J Nucl Med 16:S142
Huk WJ, Mahlstedt J (1983) Intracystic radiotherapy (90Y) of craniopharyngiomas: CT-guided stereotaxic implantation of indwelling drainage system. AJNR 4:803–806
Humm JL, Charlton DE (1989) A new calculational method to assess the therapeutic potential of Auger electron emission. Int J Radiat Oncol Biol Phys 17:351–360
Humm JL, Cobb LM (1990) Nonuniformity of tumor dose in radioimmunotherapy. J Nucl Med 31:75–83
Hundeshagen H (1983) Postoperative diagnosis and therapy of thyroid carcinoma by nuclear medicine. Eur J Nucl Med 8: 541–545
Hurley RJ, Becker DV (1983) The use of radioiodine in the management of thyroid cancer. In: Freeman LM, Weissman HS (eds) Nuclear Medicine Annual 1983. Raven Press, New York, pp 348–349
Jackson GL, Blosser NM (1981) Intracavitary chromic phosphate (32P) colloidal suspension therapy. Cancer 48:2596–2598
Jakubowski W, Feltynowski T, Januszewicz W, Graban W, Leowska L, Pacho R (1985)131I-meta-iodobenzylguanidine in localization and treatment of pheochromocytoma. Nucl Med Commun 6:586
Kaplan WD, Zimmerman RE, Bloomer WD, Knapp RC, Adelstein SJ (1981) Therapeutic intraperitoneal 3ZP: a clinical assessment of the dynamics of distribution. Radiology 138:683–688
Ketring AR (1987)153Sm-EDTMP and 186 Re-HEDP as bone therapeutic radiopharmaceuticals. Nucl Med Biol 14:223–232
Khafagi F, Egerton-Vernon J, Doorn T van, Foster W, McPhee 113, Allison RWG (1987) Localization and treatment of familial malignant nonfunctional paraganglioma with iodine-131 MIBG: report of two cases. J Nucl Med 28:528–531
Khafagi FA, Shapiro B, Fig LM, Mallette S, Sisson JC (1989) Labetalol reduces iodine-131 MIBG uptake by pheochromocytoma and normal tissues. J Nucl Med 30:481–489
Kimmig BN (1988) Selektive Strahlentherapie endokriner Tumoren: Pharmakokinetik und Dosimetrie bei der Radiojodtherapie von Schilddriisenkarzinomen and bei der MIBG-Therapie neuroektodermaler Tumoren. Enke, Stuttgart
Klaassen D, Starreveld A, Shelley W, Miller A, Boyes D, Gerulath A, Levitt M (1985) External beam pelvic radiotherapy plus intraperitoneal radioactive chromic phosphate in early stage ovarian cancer: a toxic combination. A Cancer Institute of Canada Clinical Trials Report. Int J Radiat Oncol Biol Phys 11:1801–1804
Kline CC, Klingensmith WC (1980) Failure of low doses of131I to ablate residual thyroid tissue following surgery for thyroid cancer. Radiology 137:773–774
Kloiber R, Molnar CP, Barnes M (1987) Sr-89 therapy for metastatic bone disease: scintigraphic and radiographic follow up. Radiology 163:719–723
Köhler G, Milstein C (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256:495–497
Kosuda S, Ishikawa M, Tamura K, Mukai M, Kubo A, Hashimoto S (1988) Iodine-131 therapy for parotid oncocytoma. J Nucl Med 29:1126–1129
Krempf M, Lumbroso J, Mornex R, Brendel AJ, Wemeau JL, Delisle, MJ, Aubert B, Carpentier P, Fleury-Goyon MC, Gibold C, Guyot M, Lahneche B, Marchandise X, Schlumberger M, Charbonnel B, Chatal JF (1991) Use of m-[131I]Iodobenzyl-guanidine in the treatment of malignant pheochromocytoma. J Clin Endocrinol Metab 72:455–461
Kutzner J, Grimm W, Brod KH, Rösler A (1982) Die Yttrium-90-Therapie von Knochenmetastasen. Dtsch Med Wochenschr 107:1360–1361
Laing AH, Ackery DM, Bayly RJ, Buchanan RB, Lewington VJ, McEwan AJB, Macleod PA, Zivanovic MA (1991) Strontium-89 chloride for pain palliation in prostatic skeletal malignancy. Br J Radiol (in press)
Lamberts SWJ, Bakker WH, Reubi J-C, Krenning EP (1990) Somatostatin-receptor imaging in the localization of endocrine tumors. N Eng J Med 323:1246–1249
Larson SM (1987) Lymphoma, melanoma, colon cancer: diagnosis and treatment with radiolabeled monoclonal antibodies. The 1986 Eugene P Pendergrass New Horizons lecture. Radiology 165:297–304
Lashford LS, Davies AG, Richardson RB, Bullimore JA, Eckert H, Kemshead JT, Coakham HB (1988) A pilot study of131I monoclonal antibodies in the leptomeningeal tumour. Cancer 61:857–868
Lattimer JC, Corwin LA, Stapleton J, Volkert WA, Ehrhardt GJ, Ketring AR, Anderson SK, Simon J, Goeckeler WF (1990) Clinical and clinicopathologic response of canine bone tumor patients to treatment with samarium-153-EDTMP. J Nucl Med 31:1316–1325
Lee VW, Shapiro JH (1983) Specific diagnosis of hepatoma using99mTc-HIDA and other radionuclides. Eur J Nucl Med 8:191–195
Leeper RD, Shimaoka K (1980) Treatment of metastatic thyroid cancer. Clin Endocrinol Metab 9:383–404
Leichner PK, Yang N-C, Frenkel TL, Loudenslager DM, Hawkins WG, Klein JL, Order SE (1988) Dosimetry and treatment planning for90Y-labeled antiferritin in hepatoma. Int J Rad Oncol Biol Phys 14:1033–1042 Le Jenne JJ, Bourguet P, Victor G, Therain F, Lemaire B, Collet H (1990) 1-131-Lipiodol in the treatment of hepatocellular carcinoma: results of a multicenter phase II study of fifty patients. Eur J Nucl Med 16: S143
Lenhard RE, Order SE, Spunberg JJ, Asbell SO, Leibel SS (1985) Isotopic immunoglobulin: a new systemic therapy for advanced Hodgkin's disease. J Clin Oncol 3:1296–1300
Lewington V, Ackery DM, Bayly RJ, Keeling DH, McEwan AJB, MacLeod PA, Porter AT, Zivanovic MA (1991) A double blind study to examine the efficacy of strontium-89 in the relief of pain caused by bone metastases secondary to prostatic carcinoma. Eur J Cancer (in press)
Lewis IJ, Lashford L, Fielding S (1990) UKCCSG study of therapeutic use of I-131 mIBG in chemoresistant neuroblastoma. Med Pediat Oncol 18:379
Marchandise X, Brendel AJ, Caudry M, Charbonnel B, Chatal JF, Lahneche B, Lumbroso J, Mornex R, Schlumberger M, Wemeau JL (1987) Treatment of malignant pheochromocytomas with I-131-MIBG. Results of a French Multicenter Study. Nucl Med 26:51–52
Martini N, Freiman AH, Watson RC, Hilaris BS (1978) Intrapericardial instillation of radioactive chromic phosphate in malignant pericardial effusion. AJR 128:639–641
Maxon HR, Thomas SR, Wen Cheng I (1981) The role of nuclear medicine in the treatment of hyperthyroidism and welldifferentiated thyroid adenocarcinoma. Clin Nucl Med 6:P87-P98
Maxon HR, Thomas SR, Hertzberg VS, Kereiakes JG, Wen Cheng I, Sperling MI, Saenger EL (1983) Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer. N Engl J Med 309:937–941
Maxon HR, Deutsch EA, Thomas SR, Libson K, Lukes SJ, Williams CC, Ali S (1988) Re-186(Sn) HEDP for treatment of multiple metastatic foci in bone: human distribution and dosimetric studies. Radiology 166:501–507
Mazzaferri EL, Young RL (1981) Papillary thyroid carcinoma: A 10 year follow-up report of the impact of therapy in 576 patients. Am J Med 70:511–518
McCowen KD, Adler RA, Ghaed N, Verdon T, Hofeldt FD (1976) Low dose radioiodide thyroid ablation in postsurgical patients with thyroid cancer. Am J Med 61:52–58
McEwan AJ, Schmidt RP, Catz Z, Hooper HR, Sloboda RS, MacDonald RN, Fields ALA (1989) Treatment of patients with metastatic carcinoid tumor with 131-I meta iodobenzylguanidine (mIBG). J Nucl Med 30:836
McKillop, Etcubanas E, Goris ML (1981) The indications for and limitations of bone scintigraphy in osteogenic sarcoma: a review of 55 patients. Cancer 48:1133–1138
McLaren A, Hetherington E, Maddalena D, Snowdon G (1990) Dysprosium165Dy hydroxide macroaggregates for radiation synovectomy - animal studies. Eur J Nucl Med 16:627–632
Menkes C-J, Verrier P, Le Go A, Delbarre F (1974) Synoviorthese radio-isotopique des articulations digitales dans la polyarthrite rhumatoide. Ann Chir 28:883–889
Metz O, Stoll W, Plenert W (1982) Meningosis prophylaxis with intrathecal198Au-colloid and methotrexate in childhood acute lymphocytic leukemia. Cancer 49:224–228
Miraldi F (1989) Monoclonal antibodies and neuroblastoma. Semin Nucl Med 19:282–294
Müller W, Fridrich R, Pavelka K (1974) Die Synoviorthese mit Yttrium-90. Dtsch Med Wochenschr 99:996–1000
Murphy S, Rosenthall DS, Weinfeld A, Briere J, Faguet GB, Knospe WH, Landaw SA, Laszlow J, Pisciotta AV, Tartaglia AP, Goldberg JD, Berk PD, Donovan PB, Wasserman LR (1982) Essential thromocythemia: response during first year of therapy with melphalan and radioactive phosphorus: a polycythemia Vera Study Group report. Cancer Treat Rep 66:1495–1500
Mwanza Chabunda C, Mey P, Tuchais C, Allain Y-M (1985) Irradiation métabolique des metastases osseuses douloureuses du carcinome prostatique par le Strontium-85. J Eur Radiother 6:89–93
Naeem M, Horne T, Hawkins LA, Bomanji J, Britton KE (1989) Follow-up of patients post therapy with131I-MIBG. Nucl Med Commun 10:226
Nelp WB, Eary JF, Press OW, Badger CC, Martin PJ, Appelbaum FR, Fisher D, Porter B, Bernstein IE (1990) Clinical response and toxicity following high dose I-131 antibody treatment of lymphoma. Eur J Nucl Med 16: S124
Nusynowitz ML, Pollard E, Benedetto AR, Lecklitner ML, Ware RW (1982) Treatment of medullary carcinoma of the thyroid with I-131. J Nucl Med 23:143–146
Ohta H, Yamamoto K, Endo K, Mori T, Hamanaka D, Shimazu A, Ikekubo K, Makimoto K, Iida Y, Konishi J, Morita R, Hata N, Horiuchi K, Yokoyama A, Torizuka K, Kuma K (1984) A new imaging agent for medullary carcinoma of the thyroid. J Nucl Med 25:323–325
Order SE, Stillwagon GB, Klein JL, Leichner PK, Siegelman SS, Fischman EK, Ettinger DS, Haulk T, Kopher K, Finney K, Surdyke M, Sels S, Leibel S (1985) Iodine 131 antiferritine, a new treatment modality in hepatoma: a Radiation Therapy Oncology Group Study. J Clin Oncol 3:1573–1582
Park CH, Suh JH, Yoo HS, Lee JT, Kim DI, Kim BS (1987) Treatment of hepatocellular carcinoma (HCC) with radiolabeled lipiodol: a preliminary report. Nucl Med Commun 8:1075–1087
Park CH, Yoo HS, Suh JH (1990) Critical evaluation of I-131Lipiodol therapy for hepatocellular carcinoma.Eur J Nucl Med 16:S143
Pecher C (1942) Biological investigations with radioactive calcium and strontium: preliminary report on the use of radioactive strontium in the treatment of metastatic bone cancer. Univ Calif Pub Pharmacol 11:117–149
Pectasides D, Stewart S, Courtenay-Luck N, Rampling R, Munro AJ, Krausz T, Dhokia B, Snook D, Hooker G, Durbin H, Taylor-Papadimitriou J, Bodmer WF, Epenetos AA (1986) Antibody-guided irradiation of malignant pleural and pericardial effusions. Br J Cancer 53:727–732
Pressman D, Keighly G (1948) The zone of activity of antibodies as determined by the use of radioactive tracers; the zone of activity of nephrotoxic anti-kidney serum. J Immunol 59:141–146
Preston DF, Spicer JA, Baranczuk RA, Fabian C, Baxter KG, Martin NL, Robinson RG (1990) Clinical results of breast cancer detection by imageable estradiol (I-123 E2). Eur J Nucl Med 16:430
Rall JE, Alpers JB, LeWallen CG, Sonenberg M, Berman M, Rawson RW (1957) Radiation pneumonitis and fibrosis: a complication of radio-iodine treatment of pulmonary metastases from cancer of the thyroid. J Clin Endocrinol 17:1263–1276
Ramacciotti C, Pretorius HT, Line BR, Goldman JM, Robbins J (1982) Ablation of nonmalignant thyroid remnants with low dose of radioactive iodine: concise communication. J Nucl Med 23:483–489
Richardson RB, Kemshead JT, Davies AG, Staddon GE, Jackson PC, Coakham HB, Lashford LS (1990) Dosimetry of intrathecal iodine 131 monoclonal antibody in cases of neoplastic meningitis. Eur J Nucl Med 17:42–48
Richart R, Sherman CD (1959) Prolonged survival in diffuse pleural mesothelioma treated with Au198. Cancer 12:799–805
Riva P, Lazzari S, Agostini M, Sarti G, Moscatelli G, Franceschi G, Spinelli A, Vecchietti G, Tassini R, Tirindelli D (1990) Intracavitary radioimmunotherapy trials in systemic gastrointestinal and ovarian carcinomas: pharmacokinetic, biologic and dosimetric problems. In: Schmidt HAE, Chambron J (eds) Nuclear medicine - quantitative analysis in imaging and function. Schattauer, Stuttgart, pp 586–588
Roberts DJ (1977)32P-sodium phosphate treatment of metastatic malignant disease. Clin Nucl Med 2:64–65
Robinson RG (1990) Editorial: systemic radioisotopic therapy of primary and metastatic bone cancer. J Nucl Med 31:1326–1327
Robinson RG, Spicer JA, Preston DF, Wegst AV, Martin NL (1987) Treatment of metastatic bone pain with strontium-89. Nucl Med Biol 14:219–222
Roesler H, Trifler J, Geiger L, Baer HU, Beer H-F, Blumgart L (1990) Superselective 90Y-resin embolization therapy of solid tumors. Eur J Nucl Med 16:439
Rutgers M, Gubbels AAT, Hoefnagel CA, Voûte PA, Smets LA (1991) A human neuroblastoma xenograft model for [131I]metaiodobenzylguanidine (MIBG) biodistribution and targeted radiotherapy. In: Evans AE, D'Angio GJ, Knudson AG, Seeger RC (eds) Advances in neuroblastoma research 3. Liss, New York (in press)
Saad MF, Guido JJ, Samaan NA (1983) Radioactive iodine in the treatment of medullary carcinoma of the thyroid. J Clin Endocrinol Metab 57:124–128
Sackmann Muriel F, Schere D, Barengols A (1976) Remission maintenance therapy for meningeal leukaemia: intrathecal methotrexate and dexamethasone versus intrathecal craniospinal irradiation with a radiocolloid. Br J Haematol 33:119–127
Sanguinetti M (1987) Considerations on131I-metaiodobenzylguan-idine therapy of six children with neuroblastoma. Med Pediat Oncol 15:212–215
Sarkar SD, Beierwaltes WH, Gill SP, Cowley BJ (1976) Subsequent fertility and birth histories of children and adolescents treated with131I for thyroid cancer. J Nucl Med 17:460–464
Schober O, Giinter H-H, Schwarzrock R, Hundeshagen H (1987) Hematologic long-term hazards after radioiodine therapy of thyroid cancer. J Nucl Med 28:581–582
Schroder LE, Maxon HR (1990) Re-186-HEDP palliation of painful skeletal metastases. Presented at the European Association of Nuclear Medicine Congress, Amsterdam, 1990
Shapiro B, Andrews J, Fig L, Carey J, Walker-Andrews S, Smith J, Ensminger W (1989) Therapeutic intra-arterial administration of yttrium-90 glass microspheres for hepatic tumors. In: Schmidt HAE, Chambron J (eds) Nuclear medicine - quantitative analysis in imaging and function. Schattauer, Stuttgart, pp 589–591
Shoop JD (1969) Functional hepatoma demonstrated with Rose Bengal scanning. Am J Roentgenol 107:51–53
Siddiqui AR, Edmondson J, Wellman HN, Hamaker RC, Lingeman RE, Park H-M, Johnston CC (1981) Feasibility of low doses of I-131 for thyroid ablation in postsurgical patients with thyroid carcinoma. Clin Nucl Med 6:158–161
Silberstein EB, Williams C (1985) Strontium-89 therapy for the pain of osseous metastases. J Nucl Med 26:345–348
Singh A, Holmes RA, Farhangi M, Volkert WA, Williams A, Stringham LM, Ketring AR (1989) Human pharmacokinetics of samarium-153 EDTMP in metastatic cancer. J Nucl Med 30:1814–1818
Sisson JC, Frager MS, Valk TW, Gross MD, Swanson DP, Wieland DM, Tobes MC, Beierwaltes WH, Thompson NW (1981) Scintigraphic localization of pheochromocytoma. N Engl J Med 305:12–17
Sisson JC, Shapiro B, Beierwaltes WH, Glowniak JV, Nakajo M, Mangner TJ, Carey JE, Swanson DP, Copp JE, Satterlee WG, Wieland DM (1984) Radiopharmaceutical treatment of malignant pheochromocytoma. J Nucl Med 24:197–206
Sisson JC, Hutchinson R, Johnston J, Mallette S, Carey J, Shapiro B, Beierwaltes WH (1987) Acute toxicity of therapeutic 1-131MIBG relates more to whole body than to blood radiation dosimetry. J Nucl Med 28:618
Sisson JC, Hutchinson RJ, Shapiro B, Zasadny KR, Normolle D, Wieland DM, Wahl RL, Singer DA, Malette SA, Mudgett EE (1990) Iodine-125-MIBG to treat neuroblastoma: preliminary report. J Nucl Med 31:1479–1485
Sledge CB, Atelier RW, Shortkroff S, Anderson RJ, Bloomer WD, Hurson BJ (1984) Intra-articular radiation synovectomy. Clin Orthop Rel Res 182:37–40
Smets L, Loesberg L, Janssen M, Metwally E, Huiskamp R (1989) Active uptake and extravesicular storage of metaiodobenzylguanidine in human SK-N-SH Cells. Cancer Res 49:2941–2944
Smith T, Crawley JCW, Shawe DJ, Gumpel JM (1988) SPELT using bremsstrahlung to quantify 9°Y uptake in Baker's cysts: its application in radiation synovectomy of the knee. Eur J Nucl Med 14:498–503
Snyder J, Gorman C, Scanlon P (1983) Thyroid remnant ablation: questionable pursuit of an ill-defined goal. J Nucl Med 24:659–665
Spencer RP (1985) An update on therapeutic uses of radiotracers in neoplastic disease. Semin Nucl Med 15:21–27
Spencer RP, Chapman CN, Rao H (1983) Thyroid carcinoma after radioiodide therapy for hyperthyroidism. Analysis based on age, latency and administered dose of I-131. Clin Nucl Med 8:216–219
Spiers FW, Beddoe AH, King SD (1976) The absorbed dose to bone marrow in the treatment of polycythaemia vera by32P. Br J Radiol 49:133–140
Spooren PFMJ, Rasker JJ, Arens RPJH (1985) Synovectomy of the knee with90Y. Eur J Nucl Med 10:441–445
Stevenson AC, Bedford J, Dolphin GW, Purrott RJ, Lloyd DC, Hill AGS, Hill HFH, Gumpel JM, Williams D, Scott JT, Ramsey NW, Bruckner FE, Fearn CBd'A (1973) Cytogenetic and scanning study of patients receiving intra-articular injections of gold-198 and yttrium-90. Ann Rheum Dis 32:112–123
Sullivan DC, Harris CC, Currie JL, Wilkinson RH, Creasman WT (1983) Observations on the intraperitoneal distribution of chromic phosphate (32P) suspension for intraperitoneal therapy. Radiology 146:539–541
Taasan V, Shapiro B, Taren JA, Beierwaltes WH, McKeever P, Wahl RL, Carey JE, Petry N, Malette S (1985) Phosphorus-32 therapy of cystic grade IV astrocytomas: technique and preliminary application. J Nucl Med 26:1335–1338
Theilade K, Bak M, Olsen K, Nielsen SL, Christensen NJ (1988) A case of malignant pheochromocytoma treated by 1311-Metaiodobenzylguanidine. Acta Oncol 27:296–297
Treuner J, Klingebiel T, Bruchelt G, Feine U, Niethammer D (1987) Treatment of neuroblastoma with131I-Metaiodobenzyl-guanidine: results and side effects. Med Pediat Oncol 15:199–202
Troncone L, Riccardi R, Montegmaggi P, Rufini V, Lasorella A, Mastrangelo R (1987) Treatment of neuroblastoma with131I-metaiodobenzylguanidine. Med Pediat Oncol 15:220–223
Troncone L, Rufmi V, Montemaggi, Danza FM, Lasorella A, Mastrangelo R (1990) The diagnosis and therapeutic utility of radioiodinated metaiodobenzylguanidine (MIBG). 5 years' experience. Eur J Nucl Med 16:325–335
Troutner DE (1987) Chemical and physical properties of radionuclides. Int J Rad Appl Instrum [B] 14:171–176
Tubiana M (1982) Thyroid cancer. In: Beckers C (ed) Thyroid diseases. Pergamon Press, Oxford, pp 187–227
Tubiana M, Flamant R, Attie E, Hayat M (1968) A study of hematological complications occurring in patients with polycythemia vera treated with32p (based on a series of 296 patients). Blood 32:536–548
Turner JH, Claringbold PG, Hetherington EL, Dorby P, Martindale AA (1989) A phase I study of Samarium-153 ethylenediaminetetramethylene phosphonate therapy for disseminated skeletal metastases. J Clin Oncol 7:1926–1931
Van Nostrand D, Neutze J, Atkins F (1986) Side effects of “rational dose” Iodine-131 therapy for metastatic well-differentiated thyroid carcinoma. J Nucl Med 27:1519–1527
Van Soesbergen RM, Hoefnagel CA, Marcuse HR, Dijkstra PF, Bernelot Moens HJ (1988) Radiosynoviorthesis of the knee: a doubleblind trial of 1 versus 5 mCi gold-198. Clin Rheumatol 7:224–230
Van 't Pad Bosch PJI, Putte LBA van de, Boerbooms AMT, Geerdink PJ (1981) Radiosynoviorthesis in haemophilic joint disease. Z Rheumatol 40:237–239
Varia M, Rosenman J, Venkatraman S, Askin F, Fowler W, Walton L, Halle J, Currie J (1988) Intraperitoneal chromic phosphate therapy after second-look laparotomy for ovarian cancer. Cancer 61:919–927
Varma VM, Beierwaltes WH, Nofal MM, Nishiyama RH, Copp JE (1970) Treatment of thyroid cancer: death rates after surgery and after surgery followed by sodium iodide I-131. JAMA 214:1437–1442
Volkert WA, Goeckeler WF, Ehrhardt GJ, Ketring AR (1991) Therapeutic radionuclides: production and decay property considerations. J Nucl Med 32:174–185
Voûte PA, Hoefnagel CA, Kraker J de, Evans AE, Hayes A, Green A (1987) Radionuclide therapy of neural crest tumors. Med Pediat Oncol 15:192–195
Voûte PA, Hoefnagel CA, Kraker J de, Valdés Olmos RA, Bakker DJ, Kleij AJ van de (1991) Results of treatment with131I-metaiodobenzylguanidine (131I-MIBG) in patients with neuroblastoma. Future prospects of zetotherapy. In: Evans AE, D'Angio GJ, Knudson AG, Seeger RC (eds) Advances in neuroblastoma research 3. Liss, new York (in press)
Wasserman LR (1971) The management of polycythemia vera. Br J Haematol 21:371–376
Wasserman LR (1976) The treatment of polycythemia vera. Semin Hematol 13:57–78
Wheldon TE, O'Donoghue JA, Hilditch TE, Barrett A (1988) Strategies for systemic radiotherapy of micrometastases using antibody-targeted131I. Radiother Oncol 11:133–142
Wheldon TE, O'Donoghue JA, Barrett A, Michalowski AS (1991) The curability of tumours of differing size by targeted radiotherapy using131I or90Y. Radiother Oncol (in press)
Williams ED, Caughey DE, Hurley PJ, John MB (1976) Distribution of yttrium 90 ferric hydroxide colloid and gold 198 colloid after injection into knee. Ann Rheum Dis 35:516–520
Wiseman JC, Halls IB, Joasoo A (1982) Two cases of lymphoma of the parotid gland following ablative radioiodine therapy for thyroid carcinoma. Clin Endocrinol 17:85–89
Young RL, Mazzaferri EL, Rahe AJ, Dorfman SG (1980) Pure follicular thyroid carcinoma: impact of therapy in 214 patients. J Nucl Med 21:733–737
Ziessman HA, Thrall JH, Yang PJ, Walker SC, Cozzi EA, Niederhuber JE, Gyves JW, Ensminger WD, Tuscan MC (1984) Hepatic arterial perfusion scintigraphy with Tc-99m MAA. Radiology 152:167–172
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hoefnagel, C.A. Radionuclide therapy revisited. Eur J Nucl Med 18, 408–431 (1991). https://doi.org/10.1007/BF02258432
Issue Date:
DOI: https://doi.org/10.1007/BF02258432